Akums launches generic formulation to treat migraine
时间:2024-09-29 04:44:07 阅读(143)
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).
It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine.
In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.
The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.
“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
上一篇:Coal production rises over 12 per cent to 664
下一篇:Yoga for Humanity- PM Modi at forefront of International Day of Yoga celebrations - See photos
猜你喜欢
- Comex gold finds a floor near $1,900 an ounce; Focus on CPI next week
- TCS Q3FY24 Results- Profit at Rs 11,058 crore, up 2% on-year; revenue beats estimates at Rs 60,583 crore
- Will Nifty touch fresh record high- Five things to watch out for before share market opening bell
- Strong macros to support rally in 2024
- Crude to trade sideways as Saudi Arabia raises prices; wait for range-bound activity to end before commencing medium positions
- Will Nifty touch fresh record high- Five things to watch out for before share market opening bell
- Xpressbees raises $40 million from Khazanah
- Zell Education introduces global career championship; a financial education scholarship
- COP28 Climate Summit- PM Modi launches Green Credit Initiative, proposes Hosting COP33 – See Pics